Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.39 |
| ▸ | GBA1 | P04062 | 2/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29483936 | 1.00 | SIGMAR1 (0.39) | SIGMAR1GBA1CHRM2CHRM1CACNA1G | |
| SCHEMBL2671674 | 1.00 | SIGMAR1 (0.39) | SIGMAR1GBA1CHRM2CHRM1CACNA1G | |
| SCHEMBL14104189 | 1.00 | SIGMAR1 (0.39) | SIGMAR1GBA1CHRM2CHRM1CACNA1G | |
| SCHEMBL24272975 | 0.80 | GBA1 (0.32) | GBA1 | |
| SCHEMBL8237680 | 0.72 | GBA1 (0.46) | SIGMAR1GBA1CHRM2CACNA1GCACNA1H | |
| SCHEMBL30616172 | 0.72 | GBA1 (0.46) | SIGMAR1GBA1CHRM2CACNA1GCACNA1H | |
| SCHEMBL13284755 | 0.71 | GBA1 (0.43) | GBA1CACNA1GCACNA1HHSD11B1CNR1 | |
| SCHEMBL16480434 | 0.71 | GBA1 (0.43) | GBA1CACNA1GCACNA1HHSD11B1CNR1 | |
| SCHEMBL596929 | 0.70 | PIM1 (0.31) | — | |
| SCHEMBL6376833 | 0.70 | SIGMAR1 (0.47) | SIGMAR1CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116940571-A | Benzisoxazole derivative and use thereof | 诺华股份有限公司 | 2023-10-24 | — | — | CN | disclosed |
| US-9518060-B2 | Substituted pyrrolo[3,4-c]pyrazoles as PKC kinase inhibitors | PFIZER INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-9518060-B2 | Substituted pyrrolo[3,4-c]pyrazoles as PKC kinase inhibitors | PFIZER INC. (US) | 2016-12-13 | — | — | US | disclosed |
| EP-2195321-B1 | 3-AMIDO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H,6H) CARBALDEHYDE DERIVATIVES AS INHIBITORS OF PROTEIN KINASE C | PFIZER (US) | 2016-10-19 | — | — | EP | disclosed |
| US-20150099743-A1 | NOVEL N-PYRIMIDIN-4-YL-3-AMINO-PYRROLO[3,4-C]PYRAZOLE DERIVATIVES AS PKC KINASE INHIBITORS | PFIZER INC. | 2015-04-09 | — | — | US | disclosed |
| US-20150099743-A1 | NOVEL N-PYRIMIDIN-4-YL-3-AMINO-PYRROLO[3,4-C]PYRAZOLE DERIVATIVES AS PKC KINASE INHIBITORS | PFIZER INC. | 2015-04-09 | — | — | US | disclosed |
| US-8183255-B2 | N-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazole derivatives as PKC kinase inhibitors | PFIZER, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183255-B2 | N-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazole derivatives as PKC kinase inhibitors | PFIZER, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8114871-B2 | 3-amido-pyrrolo[3,4-C]pyrazole-5(1H,4H,6H) carbaldehyde derivatives | PFIZER INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114871-B2 | 3-amido-pyrrolo[3,4-C]pyrazole-5(1H,4H,6H) carbaldehyde derivatives | PFIZER INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20100130501-A1 | NOVEL 3-AMINO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H, 6H) CARBALDEHYDE DERIVATIVES | PFIZER INC. | 2010-05-27 | — | — | US | disclosed |
| US-20100130501-A1 | NOVEL 3-AMINO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H, 6H) CARBALDEHYDE DERIVATIVES | PFIZER INC. | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130501-A1 | NOVEL 3-AMINO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H, 6H) CARBALDEHYDE DERIVATIVES | DPP3, IAPP, GPR119 | SIGMAR1 3234/4885GBA1 2103/4885CHRM2 757/4885 |
| US-20150099743-A1 | NOVEL N-PYRIMIDIN-4-YL-3-AMINO-PYRROLO[3,4-C]PYRAZOLE DERIVATIVES AS PKC KINASE INHIBITORS | PRKCB, PRKCA, PRKCQ | SIGMAR1 3243/4885GBA1 3986/4885CHRM2 1478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.